Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.78 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22363032 | 1.00 | ABL1 (1.00) | ABL1LRRK2KITPDGFRAMAP4K1 | |
| SCHEMBL22362744 | 1.00 | ABL1 (1.00) | ABL1LRRK2KITPDGFRAMAP4K1 | |
| SCHEMBL22362836 | 0.91 | ABL1 (1.00) | ABL1LRRK2KITPDGFRAMAP4K1 | |
| SCHEMBL22362821 | 0.91 | ABL1 (1.00) | ABL1LRRK2KITPDGFRAMAP4K1 | |
| SCHEMBL22362814 | 0.87 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL29285135 | 0.87 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL29720147 | 0.87 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL22363109 | 0.87 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL31037962 | 0.87 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL22363025 | 0.85 | ABL1 (1.00) | ABL1LRRK2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113454082-B | Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases | 第一生物治疗股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-113454082-B | Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases | 第一生物治疗股份有限公司 | 2024-07-02 | — | — | CN | disclosed |